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ABSTRACT 
A simple, rapid, precise, accurate and cost effective stability-indicating reversed phase (RP) HPLC related substance method-1 was validated 
for Hydralazine Hydrochloride (HYD HCl) in Active pharmaceutical ingredient. All the analytical parameters were determined as per ICH 
Q2B guidelines. Good chromatographic separation was achieved with Inertsil ODS 3V column (4.6 mm x 250 mm, 5 μm particle size) at a 
wavelength of 230 nm using phosphate buffer pH 2.5 and acetonitrile as mobile phase A and Methanol as mobile phase B with gradient 
programming with a flow rate of 1.0 ml/ min. The Resolution between Hydralazine peak and impurity-A should not be less than 3.0. From 
the statistical treatment of the linearity data of Hydralazine HCl, it is clear that the response of Hydralazine HCl is linear between 50 % to 
150 % level. The correlation coefficient is greater than 0.998. The developed method showed good linearity, Accuracy, reproducibility, 
precision and robustness and can be suitably applied for the routine quality control analysis in the estimation of commercial formulations. 
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INTRODUCTION 
Hydralazine HCl is chemically 1- hydrazinylphthalazine. 
With molecular formula- C8H8N4 and 160.17 mg molecular 
weight. It is freely soluble in water and sparingly soluble in 
methaline chloride. Hydralazine is a direct-acting smooth 
muscle relaxant. It is used as an antihypertensive agent in 
cases like preeclampsia (a condition in pregnancy 
characterized by high blood pressure). Hydralazine HCl 
acts by increasing cyclic guanosine mono-phosphate 
(cGMP) levels which causes an increase in the activity of 
protein kinase G (PKG). This results in blood vessel 
relaxation and causes dilation of arteries and arterioles1-3. 
 
Figure 1: Chemical structure of Hydralazine HCl  
Objective of Study 
Literature survey revealed that Methods for the 
determinations of Hydralazine HCl include HPLC, Gas 
chromatography, simultaneous spectrophotometric 
determination and other methods. Literature survey 
reveals that different assay methods like 
spectrophotometry, spectrofluorometry, oxidimetry, and 
HPLC are available for the validation of Hydralazine 
hydrochloride in drug substances, But none of these 
methods are found suitable for routine quality control 
studies due to the following reasons like poor sensitivity, 
longer run time, using costly solvent, suitable at higher 
concentration only, extraction procedure involved in 
sample preparation 4-6. Based on this, it was felt necessary 
to develop a validated simple, selective and sensitive HPLC 
method for the determination of Hydralazine 
hydrochloride in drug substances. The proposed method 
has been demonstrated superior to the existing procedures 
due to its sensitivity, speed, accuracy and it is suitable for 
routine quality control analysis. This proposed method can 
be successfully employed for quality control during 
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manufacture and for assessment of the stability of drugs in 
drug substances 6-10. 
EXPERIMENTAL WORK:  
Chromatographic Conditions: 
Column: Inertsil ODS-3V, 250 x 4.6mm, 5.0μm 
Detector wavelength: UV at 230 nm 
Flow rate: 1.0mL / min. 
Temperature: 30°C 
Sample temperature: 10°C 
Injection volume: 10μL 
Run time : 70 minutes 
Diluent: Water pH adjusted to 3.2 with Orthophosphoric 
acid. 
Rinsing solution: Water: Acetonitrile (1:1) v/v 
Preparation of Mobile phase: 
Mobile phase A: Weigh and transfer about 0.68 g of 
potassium dihydrogen phosphate in 2000mL Water, 
sonicate to dissolve and adjust the pH to 2.5 with dilute 
Orthophosphoric acid, filter thorough 0.45µ. 
Mobile phase B: Methanol 
Gradient Program: 
Time (minutes) Solution A Solution B 
0 90 10 
10 90 10 
45 35 65 
50 30 70 
60 30 70 
61 90 10 
70 90 10 
 
Standard Stock solution-A: Weigh and transfer accurately 
15.0 mg of Impurity-A reference standard, 15.0 mg of 
Impurity-B reference standard, 15.0 mg of Impurity-C 
reference standard into a 100 mL volumetric flask, add 10 
mL of Methanol. sonicate to dissolve, add diluent and make 
up to volume with diluent and mix. 
Standard Stock solution-B: Weigh and transfer accurately 
10.0 mg of Impurity-D reference standard in to 100mL 
volumetric flask, add approximately 50 mL of 10 % v/v 
Orthophosphoric acid solution in water and sonicate to 
dissolve and make up to mark with 10 % v/v 
Orthophosphoric acid solution. 
Standard Stock solution-C: Weigh and transfer accurately 
25.0 mg of Hydralazine Hydrochloride reference standard 
in to 100 mL volumetric flask, add about 50 mL of diluent 
and sonicate to dissolve and make up to mark with diluent. 
Standard stock solution-D: Transfer 5.0 mL of standard 
stock solution-A, B and 2.0 mL of standard stock solution-C 
in to a 50 mL volumetric flask and dilute to mark with 
diluent. 
Standard solution: Transfer 5.0 mL of standard stock 
solution-D in to a 50 mL volumetric flask and dilute up to 
mark with diluent. 
System suitability solution: Weigh and transfer accurately 
20.0 mg of Hydralazine Hydrochloride reference standard 
in 20 mL volumetric flask add standard solution, sonicate 
to dissolve and dilute up to the mark with standard 
solution. 
Test Sample solution: Weigh and transfer accurately 50.0 
mg of sample in to 50 mL volumetric flask add diluent, 
sonicate to dissolve and dilute up to the mark with diluent. 
Impurity E Stock solution preparation: Weigh and transfer 
accurately 10.0 mg of Impurity-E reference standard in to 
100 mL volumetric flask, add about 50 mL of diluent and 
sonicate to dissolve and make up to mark with diluent. 
Impurity F Stock solution preparation: Weigh and transfer 
accurately 10.0 mg of Impurity-F reference standard in to 
100 mL volumetric flask, add about 50 mL of solvent 
mixture (Acetonitrile: methanol) and sonicate to dissolve 
and make up to mark with Solvent mixture. 
Hydrochloric acid, Impurity E and Impurity F peak 
Identification Solution: Transfer 4.5mL of conc. 
Hydrochloric acid in to 10 mL volumetric flask and add 1.0 
mL each Impurity E and Impurity F stock solution and 
diluted up to mark with diluent.  
Note: Inject freshly prepared system suitability solution, 
standard solution and Test solution 
Procedure:  Inject Blank (diluent), system suitability 
preparation, standard solution six replicates and Test 
preparation in duplicate. Hydrazine peak is eluting at the 
retention time of about 6.0 minutes under the given 
chromatographic condition. The relative retention times of 
all components are as follows. 
Table 1: Name of component with relative retention 
time 
Name of the component Relative retention 
time (RRT) 
Hydralazine Hydrochloride 1.00 
Impurity-A 3.0 
Impurity-B 4.9 
Impurity-C 5.5 
Impurity-D 6.8 
Impurity-E 7.1 
Impurity-F 8.3 
 
Evaluation of System suitability: The system is suitable for 
analysis, if and only if, (a). The Resolution between 
Hydralazine peak and impurity-A should not be less than 
3.0 and (b). %RSD for area of six replicate injections of 
standard solution for each component should be not more 
than 5.0 
Note: Disregard the peaks due to blank, Hydrochloric acid, 
Impurity E and Impurity F. 
Calculation:  Calculate impurity-A, impurity-B, impurity-C, 
impurity- D and any other individual impurity and total 
impurities by the following formula 
 
%Impurity A /%Impurity B/%Impurity C/%Impurity D  
 =    Area of impurity in sample X  Wt. of impurity.std (mg) X 5 X 5X 50 X P1  
             Avg.area of Impurity Std. X100 X 50 X 50 X Sample Weight (mg) 
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% any other individual impurity: 
                             =   Area of any other individual impurity X wt of  Hydralazine.std (mg) X 2 X 5 X 50 X P2 
                   Avg.peak area of Hydralazine in Standard X 100 X 50 X50 X Sample Weight(mg)  
Where, 
P1=Potency of Impurity standard 
P2=Potency of Hydralazine HCl standard 
%Total impurities = %Impurity A+% of Impurity B+% Impurity C+%Impurity D +% Total other impurities      
Table 2: Specification limit of impurities and standard details 
Sr. No Name of the Component Specification 
1 Impurity-A Not more than 0.15% 
2 Impurity-B Not more than 0.15% 
3 Impurity-C Not more than 0.15% 
4 Impurity-D Not more than 0.10% 
7 Any other individual impurity Not more than 0.10% 
8 Total impurities Not more than 1.0 % 
 
Standard Details: 
Standard Name Potency  
Hydralazine Hydrochloride 
standard 
99.7 
Impurity-A(Phthalazine) 98.8 
Impurity-B 96.7 
Impurity-C 99.6 
Impurity-D 96.6 
Impurity-E 94.3 
Impurity-F 94.2 
Hydralazine Hydrochloride 
sample 
NA 
Hydrazine dihydrochloride 100.0 
 
RESULTS AND DISCUSSION 
Specificity: Blank (diluent), system suitability solution, 
diluted standard solution, all known impurity solutions 
individually, sample solution and sample solution spiked 
with all known impurities at specification level were 
prepared and injected into the HPLC equipped with a 
photodiode array detector and analysed. Peak purity 
passed for Hydralazine and its related impurities in control 
sample and spiked sample. Data is reported in Table 3 and 
Figure 2, 3,4 and 5. 
  
 
Figure 2: Blank and System Suitability chromatogram 
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Figure 3: Standard Solution with peak purity chromatogram 
 
 
Figure 4: Sample Solution with peak purity chromatogram 
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Figure 5: Spike Solution with peak purity chromatogram 
 
Table: 3 Peak purity information (For Spiked solution) 
Name of the compound Purity angle Purity Threshold Peak Purity Result 
Impurity A 1.870 3.983 Pass 
Impurity B 8.994 10.747 Pass 
Impurity C 0.948 2.545 Pass 
Impurity D 1.285 1.608 Pass 
 
From the above data, it is clear that, Hydralazine, Impurity-
A, Impurity-B, Impurity-C and Impurity-Dare well 
separated from each other and Hydralazine peak. There is 
no interference of Blank at the retention time of all known 
impurities and unknown Impurities. Peak Purity is passes 
for Hydralazine peak and all known impurities. Based on 
the above data method is Specific. 
Solution Stability: From the below given data it is clear 
that, spiked solution is not stable at sample cooler 
temperature of 10°C since Impurity B area is decreasing. 
So it is recommending that spiked solutions should be 
prepared freshly. Data reported in table no. 4. 
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Table 4: solution stability data for spiked solution at 10°C Sample cooler temperature: 
S. N. Sample ID Impurity A Area % Diff with initial Impurity B Area % Diff with initial 
1 Initial 198105 --- 51493 --- 
2 Sample solution after 1hrs 197877 -0.12 23719 -14.02 
3 Sample solution after 2hrs 195653 -1.12 12680 -5.57 
4 Sample solution after 5hrs 195102 -0.28 4795 -3.98 
5 Sample solution after 12hrs 191853 -1.64 3235 -0.79 
6 Sample solution after 18hrs 194241 1.21 2990 -0.12 
7 Sample solution after 24hrs 193899 -0.17 2956 -0.02 
 
Limit of Detection and Limit of Quantification: Based on determination of Prediction linearity, six replicate injections 
were made for LOD & LOQ. Details summarized in the given Table 5. 
Table 5:  for LOD and LOQ Establishment 
Solution name 
Concentration (%) 
Impurity A Impurity B Impurity C Impurity D Hydralazine 
Linearity at 1% solution 0.002 0.001 0.002 0.005 0.001 
Linearity at 5% solution 0.008 0.007 0.008 0.010 0.005 
Linearity at 10% solution 0.015 0.015 0.015 0.015 0.010 
Linearity at 15% solution 0.023 0.022 0.023 0.019 0.015 
Linearity at 20% solution 0.030 0.029 0.030 0.024 0.020 
Linearity at 25% solution 0.038 0.037 0.038 0.005 0.025 
Slope of calibration curve(S) 1303819.957 359622.915 616594.628 312992.951  290112.650 
Standard Deviation of 
 Response STEYX (σ) 
778.732 119.039 163.076 98.753 55.039 
LOD (in %) 0.002 0.001 0.001 0.001 0.001 
LOQ (in %) 0.006 0.003 0.003 0.003 0.002 
 
The predicted LOD and LOQ values of Hydralazine, 
impurity B, impurity C and Impurity D are Low and not 
reproducible. So LOD and LOQ Values are considering from 
5% linearity and 10% Linearity respectively. These values 
shall be further confirmed by precision and accuracy 
studies. 
 
LOD Confirmation and LOQ Precision: The Resolution 
between Hydralazine peak and Impurity A peak is 23.4 
(NLT 3.0).  %RSD of six replicates of standard solution is 
Complies (NMT 5.0%). System suitability parameter 
Complies. From the below given results, it is concluded that 
method is precise at LOQ Level. All individual known 
impurities were detectable at LOD level concentration. 
 
Table 6: Standard solution and all individual known impurities: 
Inj. No 
Area of 
Hydralazine 
Area of Impurity-A 
Area of 
Impurity-B 
Area of Impurity-
C 
Area of Impurity-D 
1 27413 202224 50291 90922 27597 
2 27600 203548 50552 90880 27855 
3 27343 203811 50771 91184 27707 
4 27700 201418 50873 90847 28099 
5 27539 202023 51930 90900 27691 
6 27385 202071 50935 90583 27634 
Avg. 27497 202516 50892 90886 27764 
STDEV 139.21 945.94 560.55 191.66 186.48 
%RSD 0.51 0.47 1.10 0.21 0.67 
 
Table 7: LOD and LOQ for All impurities and API: 
S.No Name of the compound LOD in % LOQ in % 
1 Hydralazine 0.005 0.015 
2 Impurity-A 0.002 0.006 
3 Impurity-B 0.0075 0.025 
4 Impurity-C 0.0075 0.025 
5 Impurity-D 0.005 0.015 
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Linearity & Range: 
A series of Standard preparations (minimum of five 
preparations) in triplicate of hydralazine hydrochloride 
and Impurity A, B, C and D working standards were 
prepared over a range of the LOQ to 150% of specification 
limits. The Correlation coefficient for hydralazine 
hydrochloride and Impurity A, B, C and D is more than 
0.99. Therefore, HPLC Method for the determination of 
related substances of hydralazine hydrochloride is linear. 
Linearity reported in Table 8-9. 
 
Table 8: Linearity of Impurity A, B, C, D and hydralazine 
Linearity levels 
Impurity-A Impurity-B Impurity-C 
Conc. in % Avg. Area Conc. in % Avg. Area Conc. in % Avg. Area 
Linearity at LOQ  0.0054 6693 0.022 7699 0.023 14712 
Linearity at 50%  0.076 99369 0.074 25606 0.075 45728 
Linearity at 80%  0.121 162812 0.118 41694 0.120 73594 
Linearity at 100%  0.151 204689 0.147 52357 0.150 91800 
Linearity at 120%  0.181 244911 0.176 62011 0.180 109165 
Linearity at 150%  0.227 308449 0.221 77619 0.225 136569 
STEYX 1264.111 344.810 381.002 
Slope 1359996.5 354232.938 601870.424 
Correlation coefficient 1.000 1.000 1.000 
            
Table 9: Linearity of Impurity A, B, C, D and hydralazine 
Linearity levels 
Impurity-D Hydralazine  
Conc. in % Avg. Area Conc. in % Avg. Area 
Linearity at LOQ  0.015 4835 0.015 4163 
Linearity at 50%  0.049 17041 0.126 14202 
Linearity at 80%  0.079 27065 0.202 22929 
Linearity at 100%  0.098 33386 0.253 28580 
Linearity at 120%  0.118 39474 0.304 33792 
Linearity at 150%  0.147 49068 0.379 41516 
STEYX 450.771 588.799 
Slope 336738.026 104104.048 
Correlation coefficient 1.000 0.999 
 
 
 
Figure 6: Linearity Graph of Impurity A, B, C, D and hydralazine 
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Accuracy: Sample of Hydralazine hydrochloride drug 
substances, were spiked with Impurities A, B, C and D at 
four different levels: LOQ, 50%, 100%, and 150% of 
specification limits (in triplicate (in total twelve 
determinations) and analysed. The Mean Recovery for 
known impurities is within limits. Therefore, the HPLC 
Method for the determination of related substances 
method-1 of Hydralazine hydrochloride in Hydralazine 
hydrochloride drug substances is accurate. Accuracy 
reported in Table 10. 
 
Table 10: Accuracy of Impurity A, B, C and D at LOQ to 150% 
Name of the component 
%Recovery  
LOQ 50% 100% 150% 
Impurity-A 89.4 98.9 99.8 101.0 
Impurity-B 92.7 96.4 95.0 92.5 
Impurity-C 101.2 100.6 99.9 100.3 
Impurity-D 93.7 96.9 98.1 101.0 
Average      
 
System precision Method precision and intermediate 
precision: 
System Precision: Six replicate injections of the standard 
solution were made & injected. RSD should not be more 
than 5.0% and The Resolution between Hydralazine peak 
and Impurity A peak is 22.1 (NLT 3.0).  The RSD of system 
precision is 2.43 %.  
Method Precision: Six Sample solutions of hydralazine 
hydrochloride spiked with Known impurities was prepared 
and injected into the HPLC, along with standard solution. 
RSD should not be more than 10.0%. RSD is less than 
10.0%. Therefore, the HPLC Method for the determination 
of related substances of hydralazine hydrochloride 
(Method-1) is precise.  
Ruggedness (Intermediate Precision): Six Sample solutions 
of the same lot of hydralazine hydrochloride, spiked with 
known impurities was made by a different analyst and 
analysed using different column on a different day and 
injected into a different HPLC, along with Standard 
solution. Overall RSD is less than 10.0%. Therefore, the 
HPLC Method for the determination of related substances 
of hydralazine hydrochloride (Method-1) is rugged. Based 
on the above data it is clear the method is Precise &Rugged. 
Precision and ruggedness data summarized in Table 11. 
 
     
Table 11: Overall RSD for method precision and intermediate precision: 
Sample ID 
Impurity-A 
(% w/w) 
Impurity-B 
(% w/w) 
Impurity-C 
(% w/w) 
Impurity-D 
(% w/w) 
Method precision-1 0.15 0.14 0.15 0.10 
Method precision-2 0.15 0.14 0.15 0.10 
Method precision-3 0.15 0.14 0.15 0.10 
Method precision-4 0.15 0.14 0.15 0.10 
Method precision-5 0.15 0.14 0.15 0.10 
Method precision-6 0.15 0.14 0.15 0.09 
Intermediate precision-1 0.15 0.14 0.15 0.10 
Intermediate precision-2 0.15 0.14 0.15 0.10 
Intermediate precision-3 0.15 0.12 0.16 0.10 
Intermediate precision-4 0.15 0.15 0.16 0.10 
Intermediate precision-5 0.15 0.14 0.15 0.09 
Intermediate precision-6 0.15 0.16 0.15 0.09 
Average 0.15 0.14 0.15 0.10 
STDEV 0.0012 0.0093 0.0025 0.0014 
% RSD 0.8 6.7 1.7 1.4 
 
 
Robustness: System suitability results meet as per criteria. 
The % RSD for content of each impurity in as such 
condition and changed condition should not be more than 
10.0. The % RSD for Contents of each impurity in spiked 
sample under test with each variable condition (mentioned 
in below table) along with as such condition is complies. 
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Table 12: Robustness of different variable conditions 
Conditions 
Impurity % w/w 
Imp. A Imp. B Imp. C Imp. D 
As Such sample 0.149 0.139 0.151 0.096 
Low Ph 0.158 0.126 0.150 0.105 
Average 0.15 0.13 0.15 0.10 
STDEV 0.0059 0.0090 0.0004 0.0063 
% RSD 3.8 6.8 0.3 6.3 
As Such sample 0.149 0.139 0.151 0.096 
High Ph 0.150 0.139 0.148 0.102 
Average 0.15 0.14 0.15 0.10 
STDEV 0.0005 0.0001 0.0016 0.0041 
% RSD 0.3 0.1 1.1 4.2 
As Such sample 0.149 0.139 0.151 0.096 
Low Temp. 0.150 0.140 0.159 0.110 
Average 0.15 0.14 0.15 0.10 
STDEV 0.0006 0.0009 0.0063 0.0100 
% RSD 0.4 0.6 4.0 9.7 
As Such sample 0.149 0.139 0.151 0.096 
High Temp. 0.146 0.132 0.142 0.084 
Average 0.15 0.14 0.15 0.09 
STDEV 0.0026 0.0047 0.0059 0.0088 
% RSD 1.7 3.5 4.0 9.8 
As Such sample 0.149 0.139 0.151 0.096 
Increase Flow 0.151 0.124 0.150 0.110 
Average 0.15 0.13 0.15 0.10 
STDEV 0.0008 0.0109 0.0005 0.0097 
% RSD 0.5 8.3 0.3 9.5 
As Such sample 0.149 0.139 0.151 0.096 
Decrease Flow 0.149 0.146 0.153 0.086 
Average 0.15 0.14 0.15 0.09 
STDEV 0.0004 0.0050 0.0015 0.0070 
% RSD 0.3 3.5 1.0 7.7 
 
CONCLUSION 
The Analytical Method for determination of Related 
substances (Method-I) by HPLC of Hydralazine 
Hydrochloride is validated as per method described. The 
validated method is found Specific, Linear, Precise, 
Accurate, Robust and Rugged for determination of Related 
substances (Method-I) by HPLC.  Hence it is concluded that 
determination of Related substances (Method-I) for 
Hydralazine Hydrochloride by HPLC can be used for 
Routine release analysis of API at Quality control 
department. 
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